Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Trial Profile

A Phase 2 Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia Harboring the 17p Deletion

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Venetoclax (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors AbbVie
  • Most Recent Events

    • 25 Apr 2019 Results of pooled analysis (n=436) assessing the influence of disease and response variables on the efficacy of venetoclax in relapsed chronic lymphocytic leukemia using data from four phase 1 or 2 clinical trials (NCT01328626,NCT01682616, NCT01889186, NCT02141282), were published in the Blood Journal.
    • 04 Dec 2018 Results (n=285) of pooled analysis of this and M13-982 study assessing efficacy of venetoclax in chronic lymphocytic leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 04 Dec 2018 Results of long term follow up of 31 patients with relapsed and refractory chronic lymphocytic Leukemia /small lymphocytic lymphoma with a known karyotype treated in one of three ongoing clinical trials NCT01328626, NCT01682616, NCT01889186, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top